POLR2A and triple-negative breast carcinoma: Taking advantage of pH-activated endolysosomal escape and drug release potential of chitosan, precise targeting of POLR2A using RNA interference (RNAi) is adopted as a therapeutic strategy for augmented cytosolic delivery of POLR2A siRNA for the treatment of human triple-negative breast cancer (TNBC) (30).